HHLR Advisors’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

HHLR Advisors’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-178,600	Closed	-$23.5M	–	108
2020 Q4	$23.5M	Hold	178,600	–	–	0.19%	53
2020 Q3	$9.03M	Hold	178,600	–	–	0.07%	65
2020 Q2	$8.51M	Hold	178,600	–	–	0.08%	56
2020 Q1	$8.75M	Hold	178,600	–	–	0.12%	47
2019 Q4	$10.3M	Hold	178,600	–	–	0.13%	42
2019 Q3	$6.42M	Hold	178,600	–	–	0.09%	52
2019 Q2	$5.55M	Hold	178,600	–	–	0.12%	36
2019 Q1	$4.19M	Hold	178,600	–	–	0.12%	27
2018 Q4	$2.46M	Buy	+178,600	New	+$2.25M	0.1%	29

HHLR Advisors's EIDX Position: Q1 2021 in Review

HHLR Advisors sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 178,600 shares — an estimated $23.5M sold.

HHLR Advisors first reported a position in EIDX in Q4 2018 and held it in 9 quarters. The position peaked at $23.5M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

HHLR Advisors reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
HHLR Advisors sold 178,600 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $23.5M.
HHLR Advisors first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2018 and held it in 9 quarters.
HHLR Advisors's Eidos Therapeutics, Inc. Common Stock position peaked at $23.5M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on HHLR Advisors's 13F filing for Q1 2021, filed 17 May 2021.